londamocitinib   Click here for help

GtoPdb Ligand ID: 11716

Synonyms: AZD-4604 | AZD4604 | example 35 [WO2018134213A1] | Jak1-IN-7
Immunopharmacology Ligand
Compound class: Synthetic organic
Comment: This is a Janus kinase 1 (JAK1) inhibitor whose chemical structure was claimed in example 35 in Astrazeneca's patent WO2018134213A1 [1]. A first time disclosure made at the 2021 XXVI EFMC International Symposium on Medicinal Chemistry (EFMC-ISMC) provided the AZD4604 name-to-structure association. AZD4604 is delivered by inhalation, and is proposed for anti-inflammatory action as an asthma therapy. The chemical structure matches the INN londamocitinib in proposed INN list 129 (August 2023).
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 10
Hydrogen bond donors 3
Rotatable bonds 10
Topological polar surface area 140.93
Molecular weight 599.21
XLogP 1.95
No. Lipinski's rules broken 0
Click here for help
Canonical SMILES COC[C@H](C(=O)Nc1cccc2c1[nH]cc2c1nc(ncc1F)Nc1cccc(c1F)S(=O)(=O)C)N1CCN(CC1)C
Isomeric SMILES COC[C@@H](N1CCN(C)CC1)C(=O)Nc1cccc2c1[nH]cc2c1c(F)cnc(Nc2c(F)c(ccc2)S(=O)(=O)C)n1
InChI InChI=1S/C28H31F2N7O4S/c1-36-10-12-37(13-11-36)22(16-41-2)27(38)33-21-8-4-6-17-18(14-31-26(17)21)25-19(29)15-32-28(35-25)34-20-7-5-9-23(24(20)30)42(3,39)40/h4-9,14-15,22,31H,10-13,16H2,1-3H3,(H,33,38)(H,32,34,35)/t22-/m1/s1
Immunopharmacology Comments
AZD4604 is a selective JAK1 inhibitor that was developed to reduce inflammation in asthma.